30 results
8-K
EX-99.1
GOSS
Gossamer Bio Inc
20 Jul 23
Interim TORREY OLE Update and PROSERA Phase 3 Design July 2023
7:50am
disease and/or who are at higher risk of disease progression, defined by risk score assessment, functional class, PVR and exercise capacity
PRE 14A
GOSS
Gossamer Bio Inc
17 Apr 23
Preliminary proxy
4:01pm
, the audit committee reviews our policies with respect to risk assessment, risk management, loss prevention and regulatory compliance. Oversight by the audit … of director’s assessment of our Chief Executive Officer’s roles and responsibilities within our company, there are significant compensation differentials
8-K
EX-99.1
6wcj24rp4apm3q1w4xa
6 Dec 22
Other Events
7:36am
8-K
r0z6e6 5wnbiknnbwfua
25 Apr 22
Results of Operations and Financial Condition
8:14am
8-K
EX-99.1
spl2hss
9 Aug 21
Gossamer Bio Announces Second Quarter 2021 Financial Results and Provides Corporate Update
4:27pm
8-K
EX-1.1
lwbf3zt
21 May 20
Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027
4:06pm
8-K
EX-1.2
zxtywyvkxmb1m3l7e
21 May 20
Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027
4:06pm
8-K
EX-99.2
t0y1fhek klp
14 May 19
Gossamer Bio Announces First Quarter 2019 Financial Results
7:31am
8-K
EX-10.1
d75xx1
3 May 19
Gossamer Bio Secures Debt Facility for Up to $150 Million
4:00pm
DEF 14A
kkrtu4dl91m 04f7sggs
30 Apr 19
Definitive proxy
4:04pm
10-K
4r5raaqp11ddv ttvc7
22 Mar 19
Annual report
4:45pm